Grants and Contributions:
Title:
MNC Collab - FOCUS2024 - Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye
Agreement Number:
1024027
Agreement Value:
$75,000.00
Agreement Date:
Nov 1, 2024 - Mar 31, 2025
Description:
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation of the safety and effectiveness of a gene, encoded in partner mRNA, in correcting an ophthalmological disease when delivered to the eye using Firm's proprietary drug delivery technology platform. The project will have two phases: (1) Formulation of proteolipid vehicle (PLV) with partner mRNA cargo followed by (2) in vitro assessment of efficacy and tolerability.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5J 4P6
Reference Number:
172-2024-2025-Q3-1024027
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
816561112
Recipient Type:
For-profit organization
Recipient's Legal Name:
Entos Pharmaceuticals Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710